Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies (Q34139859)

31 July 2017

Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies (English)

1 reference

31 July 2017

anti-retroviral agent

0 references

1 reference

0 references

1

Matthias Egger

0 references

Geneviève Chêne

3

Geneviève Chêne

1 reference

Antonella d'Arminio Monforte

31 July 2017

8

Antonella D'Arminio Monforte

1 reference

31 July 2017

Dominique Costagliola

7

Dominique Costagliola

0 references

Schlomo Staszewski

13

Schlomo Staszewski

1 reference

31 July 2017

Margaret May

2

0 references

Caroline Sabin

Caroline A Sabin

16

0 references

Jens Lundgren

Jens D Lundgren

11

0 references

Robert S Hogg

Robert S Hogg

15

0 references

Michael John Gill

M John Gill

17

0 references

François Dabis

6

François Dabis

1 reference

31 July 2017

5

Bruno Ledergerber

1 reference

31 July 2017

4

Andrew N Phillips

1 reference

31 July 2017

12

Amy C Justice

1 reference

31 July 2017

19

Jonathan A C Sterne

1 reference

31 July 2017

10

Peter Reiss

1 reference

31 July 2017

14

Catherine Leport

1 reference

31 July 2017

Frank de Wolf

9

1 reference

31 July 2017

Bernd Salzberger

18

1 reference

31 July 2017

ART Cohort Collaboration

20

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 July 2002

1 reference

31 July 2017

1 reference

31 July 2017

360

1 reference

31 July 2017

9327

1 reference

31 July 2017

119-129

1 reference

Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study

31 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909411-4

7 January 2021

Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909411-4

7 January 2021

Community-based approaches to HIV treatment in resource-poor settings

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909411-4

7 January 2021

Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909411-4

7 January 2021

CD4 cell count as a surrogate endpoint in HIV clinical trials: a meta-analysis of studies of the AIDS Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909411-4

7 January 2021

Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: a meta-analysis. HIV Surrogate Marker Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909411-4

7 January 2021

Clinical Outcome of Patients with HIV-1 Infection according to Immunologic and Virologic Response after 6 Months of Highly Active Antiretroviral Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909411-4

7 January 2021

Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909411-4

7 January 2021

Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909411-4

7 January 2021

Regional differences in use of antiretroviral agents and primary prophylaxis in 3122 European HIV-infected patients. EuroSIDA Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909411-4

7 January 2021

Zidovudine and stavudine sequencing in HIV treatment planning: findings from the CHORUS HIV cohort

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909411-4

7 January 2021

Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909411-4

7 January 2021

Predictors of long-term increase in CD4(+) cell counts in human immunodeficiency virus-infected patients receiving a protease inhibitor-containing antiretroviral regimen

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909411-4

7 January 2021

Modeling changes in CD4-positive T-lymphocyte counts after the start of highly active antiretroviral therapy and the relation with risk of opportunistic infections: the Aquitaine Cohort, 1996-1997

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909411-4

7 January 2021

The changing pattern of admissions to a London hospital of patients with HIV: 1988-1997. Royal Free Centre for HIV Medicine.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909411-4

7 January 2021

Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909411-4

7 January 2021

Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909411-4

7 January 2021

A new look at the statistical model identification

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909411-4

7 January 2021

Bayesian measures of model complexity and fit

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909411-4

7 January 2021

Assessing the generalizability of prognostic information

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909411-4

7 January 2021

Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909411-4

7 January 2021

A Clinically Prognostic Scoring System for Patients Receiving Highly Active Antiretroviral Therapy: Results from the EuroSIDA Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909411-4

7 January 2021

Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909411-4

7 January 2021

Association of the CCR5delta32 mutation with improved response to antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909411-4

7 January 2021

Multicenter comparison of three commercial methods for quantification of human immunodeficiency virus type 1 RNA in plasma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909411-4

7 January 2021

Association of Cancer With AIDS-Related Immunosuppression in Adults

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909411-4

7 January 2021

Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909411-4

7 January 2021

HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909411-4

7 January 2021

Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909411-4

7 January 2021

Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909411-4

7 January 2021

Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909411-4

7 January 2021

Differences in mortality rates and causes of death between HIV positive and HIV negative intravenous drug users

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909411-4

7 January 2021

Impact of the AIDS epidemic on morbidity and mortality among intravenous drug users in a New York City methadone maintenance program

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909411-4

7 January 2021

Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909411-4

7 January 2021

Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, France, 1996-1998. Groupe dEpidémiologie Clinique de Sida en Aquitaine (GECSA)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909411-4

7 January 2021

Impact of opportunistic disease on survival in patients with HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909411-4

7 January 2021

Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909411-4

7 January 2021

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909411-4

7 January 2021

Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909411-4

7 January 2021

Immune restoration with antiretroviral therapies: implications for clinical management

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909411-4

7 January 2021

Hit HIV-1 hard, but only when necessary

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909411-4

7 January 2021

Highly active antiretroviral therapy and coronary heart disease: the need for perspective.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909411-4

7 January 2021

The need for randomization in the study of intended effects.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909411-4

7 January 2021

10.1016/S0140-6736(02)09411-4

Identifiers

DOI

1 reference

31 July 2017

1 reference